aluates Reports

$ 0.0

Automative

Global Talacotuzumab Market Research Report 2026

Published Date: 2026-05-15

Report Code: QYRE-Auto-9M20529

BUY CHAPTERS

Global Talacotuzumab Market Research Report 2026

Code: QYRE-Auto-9M20529

Report

2026-05-15

Pages:97

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

ADC

Overland Pharmaceuticals

ADC Therapeutics SA（ADCT）

Overland ADCT BioPharma (Shanghai)

Talacotuzumab Market Size

The global Talacotuzumab market was valued at US$ 73.00 million in 2025 and is anticipated to reach US$ 115 million by 2032, at a CAGR of 4.9% from 2026 to 2032.

Talacotuzumab Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Talacotuzumab competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Loncastuximab tesirine (trade name Zynlonta) is a humanized CD19-targeted antibody-drug conjugate (ADC). It consists of a CD19-targeted monoclonal antibody, a cleavable linker, and a pyrrolobenzodiazepine (PBD) dimer toxin. It is mainly indicated for the treatment of CD19-positive B-cell malignancies such as relapsed or refractory diffuse large B-cell lymphoma. Its mechanism of action involves the specific binding of the antibody to the CD19 antigen on the surface of tumor cells, followed by internalization into the cells and release of the toxin. The toxin induces interstrand DNA crosslinks to block DNA replication and transcription, thereby killing tumor cells. Featuring high targeting specificity and potent antitumor activity, it provides an important therapeutic option for lymphoma patients who have received multiple prior lines of therapy.In 2025, global Loncastuximab production reached approximately 7,360 vials

As one of the first CD19-targeted antibody-drug conjugates launched globally, loncastuximab tesirine holds an important position in the field of relapsed and refractory lymphoma due to its unique PBD toxin mechanism and precise targeting. However, its overall market size is constrained by its current approved indications. With a steady commercialization process, it mainly targets a niche patient population receiving later-line therapy, showing moderate market growth and focusing on consolidating its existing therapeutic position in the short term. In the competitive landscape, the drug faces intense pressure from CD19-targeted CAR-T therapies, bispecific antibodies, and similar ADCs, with its differentiated advantages lying in convenient administration and accessibility. Its long-term growth potential highly depends on the expansion to second-line and frontline indications, the development of combination therapies, and global market penetration. If key clinical progress proceeds smoothly, it is expected to break through current market constraints and further expand its share in targeted therapies for B-cell lymphoma.

This report delivers a comprehensive overview of the global Talacotuzumab market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Talacotuzumab. The Talacotuzumab market size, estimates, and forecasts are provided in terms of sales volume (Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Talacotuzumab market comprehensively. Regional market sizes by Type, by Application, by Dosage Form, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Talacotuzumab manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Talacotuzumab Market Report

Report Metric	Details
Report Name	Talacotuzumab Market
Accounted market size in 2025	US$ 73.00 in million
Forecasted market size in 2032	US$ 115 million
CAGR	4.9%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	10 mg / vial 5 mg/mL
Segment by Dosage Form	Lyophilized Powder Reconstituted Solution
Segment by Sales Channels	Hospitals Retail Online
by Application	Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma Other CD19-Positive B-Cell Malignancies Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	ADC Therapeutics SA（ADCT）, Overland Pharmaceuticals, Overland ADCT BioPharma (Shanghai)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Dosage Form, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Talacotuzumab manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Talacotuzumab sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Talacotuzumab Market growing?

Ans: The Talacotuzumab Market witnessing a CAGR of 4.9% during the forecast period 2026-2032.

What is the Talacotuzumab Market size in 2032?

Ans: The Talacotuzumab Market size in 2032 will be US$ 115 million.

Who are the main players in the Talacotuzumab Market report?

Ans: The main players in the Talacotuzumab Market are ADC Therapeutics SA（ADCT）, Overland Pharmaceuticals, Overland ADCT BioPharma (Shanghai)

What are the Application segmentation covered in the Talacotuzumab Market report?

Ans: The Applications covered in the Talacotuzumab Market report are Relapsed Or Refractory Diffuse Large B-Cell Lymphoma, Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma, Other CD19-Positive B-Cell Malignancies, Others

What are the Type segmentation covered in the Talacotuzumab Market report?

Ans: The Types covered in the Talacotuzumab Market report are 10 mg / vial, 5 mg/mL

1 Talacotuzumab Market Overview

1.1 Product Definition

1.2 Talacotuzumab by Type

1.2.1 Global Talacotuzumab Market Value by Type: 2025 vs 2032

1.2.2 10 mg / vial

1.2.3 5 mg/mL

1.3 Talacotuzumab by Dosage Form

1.3.1 Global Talacotuzumab Market Value by Dosage Form: 2025 vs 2032

1.3.2 Lyophilized Powder

1.3.3 Reconstituted Solution

1.4 Talacotuzumab by Sales Channels

1.4.1 Global Talacotuzumab Market Value by Sales Channels: 2025 vs 2032

1.4.2 Hospitals

1.4.3 Retail

1.4.4 Online

1.5 Talacotuzumab by Application

1.5.1 Global Talacotuzumab Market Value by Application: 2025 vs 2032

1.5.2 Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

1.5.3 Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

1.5.4 Other CD19-Positive B-Cell Malignancies

1.5.5 Others

1.6 Global Talacotuzumab Market Size Estimates and Forecasts

1.6.1 Global Talacotuzumab Revenue 2021–2032

1.6.2 Global Talacotuzumab Sales 2021–2032

1.6.3 Global Talacotuzumab Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 Talacotuzumab Market Competition by Manufacturers

2.1 Global Talacotuzumab Sales Market Share by Manufacturers (2021–2026)

2.2 Global Talacotuzumab Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Talacotuzumab Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Talacotuzumab, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Talacotuzumab, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Talacotuzumab, Product Types and Applications

2.7 Global Key Manufacturers of Talacotuzumab, Date of Entry into the Industry

2.8 Global Talacotuzumab Market Competitive Situation and Trends

2.8.1 Global Talacotuzumab Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Talacotuzumab Players Market Share by Revenue

2.8.3 Global Talacotuzumab Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Talacotuzumab Market Scenario by Region

3.1 Global Talacotuzumab Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Talacotuzumab Sales by Region: 2021–2032

3.2.1 Global Talacotuzumab Sales by Region: 2021–2026

3.2.2 Global Talacotuzumab Sales by Region: 2027–2032

3.3 Global Talacotuzumab Revenue by Region: 2021–2032

3.3.1 Global Talacotuzumab Revenue by Region: 2021–2026

3.3.2 Global Talacotuzumab Revenue by Region: 2027–2032

3.4 North America Talacotuzumab Market Facts & Figures by Country

3.4.1 North America Talacotuzumab Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Talacotuzumab Sales by Country (2021–2032)

3.4.3 North America Talacotuzumab Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Talacotuzumab Market Facts & Figures by Country

3.5.1 Europe Talacotuzumab Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Talacotuzumab Sales by Country (2021–2032)

3.5.3 Europe Talacotuzumab Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Talacotuzumab Market Facts & Figures by Region

3.6.1 Asia Pacific Talacotuzumab Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Talacotuzumab Sales by Region (2021–2032)

3.6.3 Asia Pacific Talacotuzumab Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Talacotuzumab Market Facts & Figures by Country

3.7.1 Latin America Talacotuzumab Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Talacotuzumab Sales by Country (2021–2032)

3.7.3 Latin America Talacotuzumab Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Talacotuzumab Market Facts & Figures by Country

3.8.1 Middle East and Africa Talacotuzumab Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Talacotuzumab Sales by Country (2021–2032)

3.8.3 Middle East and Africa Talacotuzumab Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Talacotuzumab Sales by Type (2021–2032)

4.1.1 Global Talacotuzumab Sales by Type (2021–2026)

4.1.2 Global Talacotuzumab Sales by Type (2027–2032)

4.1.3 Global Talacotuzumab Sales Market Share by Type (2021–2032)

4.2 Global Talacotuzumab Revenue by Type (2021–2032)

4.2.1 Global Talacotuzumab Revenue by Type (2021–2026)

4.2.2 Global Talacotuzumab Revenue by Type (2027–2032)

4.2.3 Global Talacotuzumab Revenue Market Share by Type (2021–2032)

4.3 Global Talacotuzumab Price by Type (2021–2032)

5 Segment by Application

5.1 Global Talacotuzumab Sales by Application (2021–2032)

5.1.1 Global Talacotuzumab Sales by Application (2021–2026)

5.1.2 Global Talacotuzumab Sales by Application (2027–2032)

5.1.3 Global Talacotuzumab Sales Market Share by Application (2021–2032)

5.2 Global Talacotuzumab Revenue by Application (2021–2032)

5.2.1 Global Talacotuzumab Revenue by Application (2021–2026)

5.2.2 Global Talacotuzumab Revenue by Application (2027–2032)

5.2.3 Global Talacotuzumab Revenue Market Share by Application (2021–2032)

5.3 Global Talacotuzumab Price by Application (2021–2032)

6 Key Companies Profiled

6.1 ADC Therapeutics SA（ADCT）

6.1.1 ADC Therapeutics SA（ADCT） Company Information

6.1.2 ADC Therapeutics SA（ADCT） Description and Business Overview

6.1.3 ADC Therapeutics SA（ADCT） Talacotuzumab Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 ADC Therapeutics SA（ADCT） Talacotuzumab Product Portfolio

6.1.5 ADC Therapeutics SA（ADCT） Recent Developments/Updates

6.2 Overland Pharmaceuticals

6.2.1 Overland Pharmaceuticals Company Information

6.2.2 Overland Pharmaceuticals Description and Business Overview

6.2.3 Overland Pharmaceuticals Talacotuzumab Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Overland Pharmaceuticals Talacotuzumab Product Portfolio

6.2.5 Overland Pharmaceuticals Recent Developments/Updates

6.3 Overland ADCT BioPharma (Shanghai)

6.3.1 Overland ADCT BioPharma (Shanghai) Company Information

6.3.2 Overland ADCT BioPharma (Shanghai) Description and Business Overview

6.3.3 Overland ADCT BioPharma (Shanghai) Talacotuzumab Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Overland ADCT BioPharma (Shanghai) Talacotuzumab Product Portfolio

6.3.5 Overland ADCT BioPharma (Shanghai) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Talacotuzumab Industry Chain Analysis

7.2 Talacotuzumab Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Talacotuzumab Production Mode & Process Analysis

7.4 Talacotuzumab Sales and Marketing

7.4.1 Talacotuzumab Sales Channels

7.4.2 Talacotuzumab Distributors

7.5 Talacotuzumab Customer Analysis

8 Talacotuzumab Market Dynamics

8.1 Talacotuzumab Industry Trends

8.2 Talacotuzumab Market Drivers

8.3 Talacotuzumab Market Challenges

8.4 Talacotuzumab Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

ADC

Overland Pharmaceuticals

ADC Therapeutics SA（ADCT）

Overland ADCT BioPharma (Shanghai)

List of Tables

Table 1. Global Talacotuzumab Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Talacotuzumab Market Value by Dosage Form (US$ Million), 2025 vs 2032

Table 3. Global Talacotuzumab Market Value by Sales Channels (US$ Million), 2025 vs 2032

Table 4. Global Talacotuzumab Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global Talacotuzumab Market Competitive Situation by Manufacturers in 2025

Table 6. Global Talacotuzumab Sales (Units) of Key Manufacturers (2021–2026)

Table 7. Global Talacotuzumab Sales Market Share by Manufacturers (2021–2026)

Table 8. Global Talacotuzumab Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global Talacotuzumab Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market Talacotuzumab Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of Talacotuzumab, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of Talacotuzumab, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of Talacotuzumab, Product Types and Applications

Table 14. Global Key Manufacturers of Talacotuzumab, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Talacotuzumab Companies by Tier (Tier 1, Tier 2, Tier 3), based on Talacotuzumab Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Talacotuzumab Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global Talacotuzumab Sales by Region (Units), 2021–2026

Table 20. Global Talacotuzumab Sales Market Share by Region (2021–2026)

Table 21. Global Talacotuzumab Sales by Region (Units), 2027–2032

Table 22. Global Talacotuzumab Sales Market Share by Region (2027–2032)

Table 23. Global Talacotuzumab Revenue by Region (US$ Million), 2021–2026

Table 24. Global Talacotuzumab Revenue Market Share by Region (2021–2026)

Table 25. Global Talacotuzumab Revenue by Region (US$ Million), 2027–2032

Table 26. Global Talacotuzumab Revenue Market Share by Region (2027–2032)

Table 27. North America Talacotuzumab Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America Talacotuzumab Sales by Country (Units), 2021–2026

Table 29. North America Talacotuzumab Sales by Country (Units), 2027–2032

Table 30. North America Talacotuzumab Revenue by Country (US$ Million), 2021–2026

Table 31. North America Talacotuzumab Revenue by Country (US$ Million), 2027–2032

Table 32. Europe Talacotuzumab Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe Talacotuzumab Sales by Country (Units), 2021–2026

Table 34. Europe Talacotuzumab Sales by Country (Units), 2027–2032

Table 35. Europe Talacotuzumab Revenue by Country (US$ Million), 2021–2026

Table 36. Europe Talacotuzumab Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific Talacotuzumab Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific Talacotuzumab Sales by Region (Units), 2021–2026

Table 39. Asia Pacific Talacotuzumab Sales by Region (Units), 2027–2032

Table 40. Asia Pacific Talacotuzumab Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific Talacotuzumab Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America Talacotuzumab Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America Talacotuzumab Sales by Country (Units), 2021–2026

Table 44. Latin America Talacotuzumab Sales by Country (Units), 2027–2032

Table 45. Latin America Talacotuzumab Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America Talacotuzumab Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa Talacotuzumab Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa Talacotuzumab Sales by Country (Units), 2021–2026

Table 49. Middle East and Africa Talacotuzumab Sales by Country (Units), 2027–2032

Table 50. Middle East and Africa Talacotuzumab Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa Talacotuzumab Revenue by Country (US$ Million), 2027–2032

Table 52. Global Talacotuzumab Sales (Units) by Type (2021–2026)

Table 53. Global Talacotuzumab Sales (Units) by Type (2027–2032)

Table 54. Global Talacotuzumab Sales Market Share by Type (2021–2026)

Table 55. Global Talacotuzumab Sales Market Share by Type (2027–2032)

Table 56. Global Talacotuzumab Revenue (US$ Million) by Type (2021–2026)

Table 57. Global Talacotuzumab Revenue (US$ Million) by Type (2027–2032)

Table 58. Global Talacotuzumab Revenue Market Share by Type (2021–2026)

Table 59. Global Talacotuzumab Revenue Market Share by Type (2027–2032)

Table 60. Global Talacotuzumab Price (US$/Unit) by Type (2021–2026)

Table 61. Global Talacotuzumab Price (US$/Unit) by Type (2027–2032)

Table 62. Global Talacotuzumab Sales (Units) by Application (2021–2026)

Table 63. Global Talacotuzumab Sales (Units) by Application (2027–2032)

Table 64. Global Talacotuzumab Sales Market Share by Application (2021–2026)

Table 65. Global Talacotuzumab Sales Market Share by Application (2027–2032)

Table 66. Global Talacotuzumab Revenue (US$ Million) by Application (2021–2026)

Table 67. Global Talacotuzumab Revenue (US$ Million) by Application (2027–2032)

Table 68. Global Talacotuzumab Revenue Market Share by Application (2021–2026)

Table 69. Global Talacotuzumab Revenue Market Share by Application (2027–2032)

Table 70. Global Talacotuzumab Price (US$/Unit) by Application (2021–2026)

Table 71. Global Talacotuzumab Price (US$/Unit) by Application (2027–2032)

Table 72. ADC Therapeutics SA（ADCT） Company Information

Table 73. ADC Therapeutics SA（ADCT） Description and Business Overview

Table 74. ADC Therapeutics SA（ADCT） Talacotuzumab Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. ADC Therapeutics SA（ADCT） Talacotuzumab Product

Table 76. ADC Therapeutics SA（ADCT） Recent Developments/Updates

Table 77. Overland Pharmaceuticals Company Information

Table 78. Overland Pharmaceuticals Description and Business Overview

Table 79. Overland Pharmaceuticals Talacotuzumab Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. Overland Pharmaceuticals Talacotuzumab Product

Table 81. Overland Pharmaceuticals Recent Developments/Updates

Table 82. Overland ADCT BioPharma (Shanghai) Company Information

Table 83. Overland ADCT BioPharma (Shanghai) Description and Business Overview

Table 84. Overland ADCT BioPharma (Shanghai) Talacotuzumab Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Overland ADCT BioPharma (Shanghai) Talacotuzumab Product

Table 86. Overland ADCT BioPharma (Shanghai) Recent Developments/Updates

Table 87. Key Raw Materials Lists

Table 88. Raw Materials Key Suppliers Lists

Table 89. Talacotuzumab Distributors List

Table 90. Talacotuzumab Customers List

Table 91. Talacotuzumab Market Trends

Table 92. Talacotuzumab Market Drivers

Table 93. Talacotuzumab Market Challenges

Table 94. Talacotuzumab Market Restraints

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Authors List of This Report

List of Figures

Figure 1. Product Picture of Talacotuzumab

Figure 2. Global Talacotuzumab Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Talacotuzumab Market Share by Type: 2025 & 2032

Figure 4. 10 mg / vial Product Picture

Figure 5. 5 mg/mL Product Picture

Figure 6. Global Talacotuzumab Market Value by Dosage Form (US$ Million), 2021–2032

Figure 7. Global Talacotuzumab Market Share by Dosage Form: 2025 vs 2032

Figure 8. Lyophilized Powder Product Picture

Figure 9. Reconstituted Solution Product Picture

Figure 10. Global Talacotuzumab Market Value by Sales Channels (US$ Million), 2021–2032

Figure 11. Global Talacotuzumab Market Share by Sales Channels: 2025 vs 2032

Figure 12. Hospitals Product Picture

Figure 13. Retail Product Picture

Figure 14. Online Product Picture

Figure 15. Global Talacotuzumab Market Value by Application (US$ Million), 2021–2032

Figure 16. Global Talacotuzumab Market Share by Application: 2025 & 2032

Figure 17. Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Figure 18. Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

Figure 19. Other CD19-Positive B-Cell Malignancies

Figure 20. Others

Figure 21. Global Talacotuzumab Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global Talacotuzumab Market Size (US$ Million), 2021–2032

Figure 23. Global Talacotuzumab Sales (Units), 2021–2032

Figure 24. Global Talacotuzumab Average Price (US$/Unit), 2021–2032

Figure 25. Talacotuzumab Report Years Considered

Figure 26. Talacotuzumab Sales Share by Manufacturers in 2025

Figure 27. Global Talacotuzumab Revenue Share by Manufacturers in 2025

Figure 28. Top 5 and Top 10 Global Talacotuzumab Players: Market Share by Revenue in Talacotuzumab in 2025

Figure 29. Talacotuzumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 30. Global Talacotuzumab Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 31. North America Talacotuzumab Sales Market Share by Country (2021–2032)

Figure 32. North America Talacotuzumab Revenue Market Share by Country (2021–2032)

Figure 33. United States Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Canada Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Europe Talacotuzumab Sales Market Share by Country (2021–2032)

Figure 36. Europe Talacotuzumab Revenue Market Share by Country (2021–2032)

Figure 37. Germany Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. France Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. U.K. Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Italy Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Russia Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Asia Pacific Talacotuzumab Sales Market Share by Region (2021–2032)

Figure 43. Asia Pacific Talacotuzumab Revenue Market Share by Region (2021–2032)

Figure 44. China Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Japan Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. South Korea Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. India Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Australia Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. China Taiwan Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Southeast Asia Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Latin America Talacotuzumab Sales Market Share by Country (2021–2032)

Figure 52. Latin America Talacotuzumab Revenue Market Share by Country (2021–2032)

Figure 53. Mexico Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Brazil Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Argentina Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Colombia Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Middle East and Africa Talacotuzumab Sales Market Share by Country (2021–2032)

Figure 58. Middle East and Africa Talacotuzumab Revenue Market Share by Country (2021–2032)

Figure 59. Turkey Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Saudi Arabia Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 61. UAE Talacotuzumab Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. Global Sales Market Share of Talacotuzumab by Type (2021–2032)

Figure 63. Global Revenue Market Share of Talacotuzumab by Type (2021–2032)

Figure 64. Global Talacotuzumab Price (US$/Unit) by Type (2021–2032)

Figure 65. Global Sales Market Share of Talacotuzumab by Application (2021–2032)

Figure 66. Global Revenue Market Share of Talacotuzumab by Application (2021–2032)

Figure 67. Global Talacotuzumab Price (US$/Unit) by Application (2021–2032)

Figure 68. Talacotuzumab Value Chain

Figure 69. Channels of Distribution (Direct Vs Distribution)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions